Compare Neurocrine Biosciences Inc (NBIX) vs Zillow Group Inc Class A (ZG) Price & Performance

Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.

Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.

Zillow Group (ZG) trades at $31.80, down 5.67% over 24 hours, amid a bearish technical signal and negative news flow. The company reported revenue of $2.58B in 2025 with a net income of $23M, marking a return to profitability after losses in prior years. However, a high P/E ratio of 131.36 suggests premium valuation, while recent earnings showed a mix of beats and misses. Multiple law firms have announced securities class action investigations related to an alleged anticompetitive agreement, contributing to investor uncertainty.

The outlook is clouded by legal risks and rich valuation, though analyst consensus remains positive with a $57.80 price target. Upside potential hinges on sustained revenue growth and margin expansion, but downside risks include litigation outcomes and competitive pressures. Investors should weigh the strong analyst buy rating against fundamental headwinds.